Evidence map›Paper›PMID 27998980›Full record

ArticleThe Journal of biological chemistry2017

Glutamate Counteracts Dopamine/PKA Signaling via Dephosphorylation of DARPP-32 Ser-97 and Alteration of Its Cytonuclear Distribution.

Akinori Nishi, Miriam Matamales, Veronica Musante, Emmanuel Valjent, Mahomi Kuroiwa, Yosuke Kitahara, Heike Rebholz, Paul Greengard, Jean-Antoine Girault, Angus C Nairn

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. The Signaling and Pharmacology of the Dopamine D1 Receptor.Frontiers in cellular neuroscience · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Akinori NishiFrom the Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan, nishia@med.kurume-u.ac.jp.
Miriam MatamalesInstitut du Fer à Moulin, INSERM, UPMC UMR-S839, 75005 Paris, France.
Veronica MusanteDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508.
Emmanuel ValjentInstitut de Génomique Fonctionnelle, Inserm U1191, UMR 5203 CNRS, Montpellier University, 34094 Montpellier, France, and.
Mahomi KuroiwaFrom the Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Yosuke KitaharaFrom the Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Heike RebholzLaboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.
Paul GreengardLaboratory of Molecular and Cellular Neuroscience, The Rockefeller University, New York, New York 10065.
Jean-Antoine GiraultInstitut du Fer à Moulin, INSERM, UPMC UMR-S839, 75005 Paris, France.
Angus C NairnDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06508.
Kurume University · JPRockefeller University · USYale University · USInserm · FRInstitut de Génomique Fonctionnelle · FRSorbonne Université · FR

Funding

THE ROLE OF DARPPS IN THE ACUTE AND CHRONIC EFFECTS OF COCAINE AND AMPHETAMINEP01DA010044 · NIDA · ROCKEFELLER UNIVERSITY · PI GREENGARD, PAUL · 1996 to 2015
$23.6M
Striatal Cell-specific Analysis of the Molecular Mechanisms of Antipsychotic DrugP50MH090963 · NIMH · ROCKEFELLER UNIVERSITY · PI FLAJOLET, MARC · 2010 to 2014
$9.8M
Yale Alzheimer Disease Research CenterP50AG047270 · NIA · YALE UNIVERSITY · PI MAROTTOLI, RICHARD · 2015 to 2019
$8.3M
NIA NIH HHS P50 AG047270NIDA NIH HHS P01 DA010044NIMH NIH HHS P50 MH090963
6 · The paper itself

Abstract

The interaction of glutamate and dopamine in the striatum is heavily dependent on signaling pathways that converge on the regulatory protein DARPP-32. The efficacy of dopamine/D1 receptor/PKA signaling is regulated by DARPP-32 phosphorylated at Thr-34 (the PKA site), a process that inhibits protein phosphatase 1 (PP1) and potentiates PKA action. Activation of dopamine/D1 receptor/PKA signaling also leads to dephosphorylation of DARPP-32 at Ser-97 (the CK2 site), leading to localization of phospho-Thr-34 DARPP-32 in the nucleus where it also inhibits PP1. In this study the role of glutamate in the regulation of DARPP-32 phosphorylation at four major sites was further investigated. Experiments using striatal slices revealed that glutamate decreased the phosphorylation states of DARPP-32 at Ser-97 as well as Thr-34, Thr-75, and Ser-130 by activating NMDA or AMPA receptors in both direct and indirect pathway striatal neurons. The effect of glutamate in decreasing Ser-97 phosphorylation was mediated by activation of PP2A. In vitro phosphatase assays indicated that the PP2A/PR72 heterotrimer complex was likely responsible for glutamate/Ca

Indexed as

AnimalsCell NucleusCyclic AMP-Dependent Protein KinasesDopamineDopamine and cAMP-Regulated Phosphoprotein 32MaleMicePhosphorylationProtein Phosphatase 2Receptors, Dopamine D1Signal TransductionCyclic AMP-Dependent Protein KinasesDopamineDopamine and cAMP-Regulated Phosphoprotein 32Ppp1r1b protein, mouseProtein Phosphatase 2Receptors, Dopamine D1CK2DARPP-32dopamineglutamatenuclear translocationprotein kinase A (PKA)protein phosphatase 2 (PP2A)protein phosphorylationstriatum

Identifiers

PMID27998980
PMCPMC5270488
OpenAlexW2566199234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.